Selective TYK2 Inhibitors Targeting the Pseudokinase Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TYK2-mediated diseases lack selective inhibitors that target the pseudokinase domain of TYK2, leading to off-target effects and side-effects associated with the inhibition of other JAK family members.
Innovation Solution
Development of compounds that selectively bind to the pseudokinase domain (JH2) of TYK2, acting as allosteric modulators or noncompetitive inhibitors, thereby reducing off-target effects and enhancing specificity over other JAK kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum JAK inhibitors are used to treat TYK2-mediated diseases, then disease treatment efficacy is improved, but off-target effects and side-effects increase due to inhibition of other JAK family members
Solution Approach 1:
The patent segments the JAK family into individual members and develops inhibitors that specifically target TYK2 while sparing other JAK family members (JAK1, JAK2, JAK3). This is achieved through selective binding to the pseudokinase domain of TYK2, allowing treatment of TYK2-mediated diseases without the off-target effects of broad-spectrum JAK inhibitors.
Solution Approach 2:
The patent applies local quality by designing compounds with specific structural features that confer selectivity for TYK2. The compounds contain heterocyclic rings and substituent patterns (such as fluorinated alkyl groups, specific heteroatom arrangements) that create local chemical environments preferentially recognized by TYK2's binding pocket, enabling selective inhibition without affecting other JAK kinases.
2Reliability
If selective TYK2 inhibitors targeting the pseudokinase domain are developed, then selectivity over other JAKs is improved, but compound structural complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying key structural parameters of the inhibitor molecules, including the type of heterocyclic ring (pyridine, pyrimidine, triazole, oxazole), the nature of substituent groups (fluorinated alkyl, alkoxyl, amino), and their positions on the core structure. These parameter variations allow optimization of selectivity for TYK2 while managing structural complexity through rational design rather than random screening.
Data Source
AI summary
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.